Specificity and function of monoclonal antibodies directed against Ewing sarcoma cells
Related Experiment Video
Updated: Nov 9, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
L R Shi1, D Eichelbauer, F Borchard
1Immunology Laboratory, Institute of Blood Coagulation and Transfusion Medicine, University of Düsseldorf, Germany.
Abstract:
A selection of 16 monoclonal antibodies has been produced against a fresh Ewing's sarcoma (ES) tumor mixed with a permanent ES cell line. The majority of antibodies identify an 80-kDa molecule, which is not detected on healthy tissues except on certain cultured monocytes. One antibody recognizes the CD2 ligand MIC2 and 2 antibodies (numbers 13 and 16) define a higher-molecular-mass antigen. Antibody 16 is also expressed on mesenchymal fibroblasts of bone marrow or fetal origin. Tumor-specific antigen expression is potentially linked to the chromosome 22 abnormality described in Ewing's sarcoma, products altered expression in tumors with the chromosome 11/22 translocation has not been shown. The putative chimeric protein on chromosome 11 is apparently not expressed to a great extent, as tested by Northern blotting; however, the fusion protein initiated on chromosome 22 and ending on chromosome 11 is readily seen on Northern blots. The altered expression of a number of cellular genes in addition to a novel gene product(s) originating from translocation events were expected to be identified by monoclonal antibodies selected by their unique binding pattern to Ewing's sarcoma (ES) cells.
Insights
Researchers developed monoclonal antibodies to identify novel antigens in Ewing
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Ewing's sarcoma (ES) is a rare bone cancer with specific chromosomal abnormalities.
- Identifying tumor-specific antigens is crucial for understanding ES pathogenesis and developing targeted therapies.
Purpose of the Study:
- To generate and characterize monoclonal antibodies against Ewing's sarcoma.
- To identify novel tumor-associated antigens and investigate their potential link to chromosomal abnormalities in ES.
Main Methods:
- Production of 16 monoclonal antibodies against ES tumor and cell lines.
- Characterization of antibody binding to tumor cells and normal tissues using techniques like Northern blotting.
- Analysis of antigen expression in relation to chromosomal translocations (e.g., t(11;22)).
Main Results:
- A majority of antibodies identified an 80-kDa molecule present on ES cells but not most healthy tissues.
- One antibody recognized the CD2 ligand MIC2.
- Two antibodies identified a higher-molecular-mass antigen, with one also found on mesenchymal fibroblasts.
Conclusions:
- Monoclonal antibodies can identify novel antigens in Ewing's sarcoma.
- The 80-kDa antigen and the higher-molecular-mass antigen are potential targets for ES research.
- Further investigation is needed to confirm the link between these antigens and the specific chromosomal translocations in ES.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle